title: A child case of CD34+, CD33-, HLA-DR-, CD7+, CD56+ stem cell leukemia with thymic involvement.
abstract: It has been reported that the CD56+/CD7+/CD3- phenotype of natural killer (NK) cells develop from the CD34+/HLA-DR- bone marrow (BM) mononuclear cell population in long-term BM culture (LTBMC). An HLA-DR-/CD33+/CD56+/CD16- myeloid/natural killer cell acute leukemia has been described. We report here a 7-year-old boy who developed stem cell acute leukemia with superior vena cava syndrome secondary to thymic involvement. Surface marker analyses revealed that the leukemia cells showed CD34+/HLA-DR-/CD33-/CD7+/CD56+ phenotype. When stimulated with phorbol ester in vitro the leukemic cells morphologically differentiated to myeloid cells developing CD13, CD15 and CD56 antigens. Our results suggest that CD34+/HLA-DR-/CD7+/CD56+ stem cell leukemia may arise from transformation of a pluripotent precursor cell, which could differentiate to both myeloid and NK cell lineages.
authors.affiliation: Department of Pediatrics, Mie University School of Medicine, Edobashi, Tsu-city, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Nagata
authors.forename: M
authors.initials: M
authors.lastname: Higashigawa
authors.forename: M
authors.initials: M
authors.lastname: Nagai
authors.forename: X L
authors.initials: XL
authors.lastname: Zhang
authors.forename: E
authors.initials: E
authors.lastname: Azuma
authors.forename: Y
authors.initials: Y
authors.lastname: Komada
authors.forename: M
authors.initials: M
authors.lastname: Sakurai
mesh_terms: D015703:Antigens, CD / Q000032:analysis; D018952:Antigens, CD34 / Q000032:analysis; D019011:Antigens, CD7 / Q000032:analysis; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis; D000951:Antigens, Neoplasm / Q000032:analysis*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001215:Asparaginase / Q000008:administration & dosage; D019002:CD56 Antigen / Q000032:analysis; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D016130:Immunophenotyping; D007694:Killer Cells, Natural / Q000737:chemistry / Q000473:pathology*; D015458:Leukemia, T-Cell / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D014411:Neoplastic Stem Cells / Q000737:chemistry / Q000473:pathology*; D012074:Remission Induction; D063268:Sialic Acid Binding Ig-like Lectin 3; D013479:Superior Vena Cava Syndrome / Q000209:etiology*; D013950:Thymus Gland / Q000473:pathology*; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D015703:Antigens, CD; D018952:Antigens, CD34; D019011:Antigens, CD7; D015214:Antigens, Differentiation, Myelomonocytic; D000951:Antigens, Neoplasm; C571163:CD33 protein, human; D019002:CD56 Antigen; D006684:HLA-DR Antigens; D063268:Sialic Acid Binding Ig-like Lectin 3; D003561:Cytarabine; D014750:Vincristine; D005047:Etoposide; D003907:Dexamethasone; D003520:Cyclophosphamide; D001215:Asparaginase; D003630:Daunorubicin